London · Delayed Price · Currency is GBP · Price in USD Aytu BioPharma Company Description
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old.
It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.
Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 102 |
| CEO | Joshua Disbrow |
Contact Details
Address: Denver Corporate Center III Denver, Delaware 80237 United States | |
| Phone | 720 437 6580 |
| Website | aytubio.com |
Stock Details
| Ticker Symbol | 0A8M |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joshua Disbrow | Chief Executive Officer |
| Ryan Selhorn | Chief Financial Officer |
| Margaret Cabano | Chief Operating Officer |